Preliminary Short-term Results of a Population of Patients Treated with MitraClip Therapy: One Center Experience

Rossana Taravella, Melchiorre Gilberto Cellura, Giuseppe Cirrincione, Salvatore Asciutto, Marco Caruso, Massimo Benedetto, Rossella Alduino, Salvatore Novo


Objectives: This retrospective analysis sought to evaluate 1-month outcomes and therapy effectiveness of a population of patients treated with MitraClip therapy. We describe in this article the preliminary results of primary effictiveness endpoint.

Background: Percutaneous Mitral Repair is being developed to treat severe mitral regurgitation (MR),with increasing real-world cases of functional MR(FMR). In the EVEREST(Endovascular Valve Edge-to-Edge Repair Study)II trial,percutaneous device showed superior safety but less reduction in MR at 1year. 4-year outcomes from EVEREST II trial showed no difference in the prevalence of moderate-severe and severe MR or mortality at 4years between surgical mitral repair and percutaneous approach.

Methods: We analysed retrospectively collected data from one center experience in Italy enrolled from January2011 to December2016. The study included 62patients[mean age74±11years, 43 men(69%)] with MR of at least grade3+. Most of patients had functional MR, were in New York Heart Association(NYHA) functional class III or IV,with a large portion(78%) of mild-to-moderate Tricuspid Regurgitation(TR). One or more clips were implanted in 67procedures(62 patients). 

Results and Conclusions: Severity of MR was reduced in all successfully treated patients,54(90%) were discharged with MR≤2+(primary effictiveness endpoint). Clinical 1-month follow-up data showed an improvement in NYHA functional class (42patients (70%) in NYHA class I-II). 60 of 62 (97 %) successfully treated patients were free from death and mitral valve surgery at 1-month follow-up. MitraClip therapy reduces functional MR with acute MR reduction to <2+ in the great majority of patients,with a large freedom from death, surgery or recurrent MR in a great portion of patients.


MitraClip; Mitral Regurgitation; Catheter-based therapy; Heart valves; NYHA functional class

Full Text:

437 HTML


Robbins JD, Maniar PB, Cotts W, Parker MA, Bonow RO, Gheorghiade M. Prevalence and severity of mitral regurgitation in chronic systolic heart failure. Am J Cardiol 2003;91:360–362. DOI: 10.1016/S0002-9149(02)03172-7.

Trichon BH, Felker GM, Shaw LK, Cabell CH, O’Connor CM. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003;91:538–543. DOI: 10.1016/S0002-9149(02)03301-5.

Franzen O,van der Heyden J, Baldus S et al. MitraClip therapy in patients with end-stage systolic heart failure. European Journal of Heart Failure 2011;13;569-576. DOI: 10.1093/eurjhf/hfr029.

Feldman T, Kar S, Rinaldi M, et al. EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009;54:686–694. DOI: 10.1016/j.jacc.2009.03.077.

Tamburino C, Ussia GP, Maisano F, et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J 2010;31:1382–1389. DOI: 10.1093/eurheartj/ehq051.

Zoghbi WA, Enriquez-Sarano M, Foster E et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777–802. DOI: 10.1016/S0894-7317(03)00335-3.

Foster E, Wasserman HS, Gray W et al. Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. Am J Cardiol 2007;100:1577–1583. DOI: 10.1016/j.amjcard.2007.06.066.

Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, Mitral Regurgitation:Recommendations. Circulation. 2014;129. DOI: 10.1161/CIR.0000000000000031.

Franzen O, Baldus S, Rudolph V, et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J 2010;31:1373–1381. DOI: 10.1093/eurheartj/ehq050.

Kotlyar E, Hayward CS, Keogh AM, Feneley M, Macdonald PS. The impact of baseline left ventricular size and mitral regurgitation on reverse left ventricular remodelling in response to carvedilol: size doesn’t matter. Heart 2004;90:800–801. DOI: 10.1136/hrt.2002.009696.

Liang YJ, Zhang Q, Fung JW, et al. Impact of reduction in early- and late-systolic functional mitral regurgitation on reverse remodelling after cardiac resynchronization therapy. Eur Heart J 2010;31: 2359–2368. DOI: 10.1093/eurheartj/ehq134.

Braun J, Bax JJ, Versteegh MI, et al. Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischemic mitral regurgitation. Eur J Cardiothorac Surg 2005;27:847–853. DOI: 10.1016/j.ejcts.2004.12.031.

Mauri L, Foster E, Glower DD, et al. 4-Year Results of a Randomized Controlled Trial of Percutaneous Repair Versus Surgery for Mitral Regurgitation. Journal of the American College of Cardiology. Vol. 62, No. 4, 2013. DOI: 10.1016/j.jacc.2013.04.030.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2. DOI: 10.17987/icfj.v2i1.4.


Copyright (c) 2017 The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.